Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.57 |
| ▸ | ALPL | P05186 | 5/20 | 0.52 |
| ▸ | AR | P10275 | 3/20 | 0.45 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.42 |
| ▸ | ACLY | P53396 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7280551 | 0.88 | ACLY (0.53) | TRPV4ALPLACLY | |
| SCHEMBL19682479 | 0.87 | TRPV4 (0.70) | TRPV4ALPLARPTGES2 | |
| SCHEMBL13211338 | 0.85 | SMN1; SMN2 (0.59) | TRPV4ALPLARPTGES2ACLY | |
| SCHEMBL694203 | 0.79 | TBXA2R (0.52) | TRPV4ARTBXA2R | |
| SCHEMBL3079216 | 0.77 | TRPV4 (0.54) | TRPV4ARRAD51TBXA2R | |
| SCHEMBL2820417 | 0.77 | TBXA2R (0.49) | TRPV4TBXA2R | |
| SCHEMBL693580 | 0.77 | AR (0.49) | TRPV4ARTBXA2R | |
| SCHEMBL739940 | 0.75 | KMT2A (0.60) | TRPV4SMN1; SMN2 | |
| SCHEMBL750886 | 0.75 | TRPV4 (0.73) | TRPV4ALPLSMN1; SMN2 | |
| SCHEMBL407215 | 0.75 | L3MBTL1 (0.64) | TRPV4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12485169-B2 | Compounds | Grey Wolf Therapeutics Limited (GB) | 2025-12-02 | — | — | US | disclosed |
| WO-2025136811-A1 | CHEMICAL COMPOUNDS AND USES THEREOF | IDEAYA BIOSCIENCES, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| CN-120025279-A | Compounds capable of modulating endoplasmic reticulum aminopeptidase 1 | 格雷沃尔夫治疗有限公司 | 2025-05-23 | — | — | CN | disclosed |
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230064417-A1 | COMPOUNDS | Grey Wolf Therapeutics Limited (GB) | 2023-03-02 | — | — | US | disclosed |
| WO-2022109001-A1 | GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC (US) | 2022-05-27 | — | — | WO | disclosed |
| EP-3883650-A1 | COMPOUNDS | Grey Wolf Therapeutics Limited (GB) | 2021-09-29 | — | — | EP | disclosed |
| CN-113056305-A | Compound (I) | 格雷沃尔夫治疗有限公司 | 2021-06-29 | — | — | CN | disclosed |
| US-9169251-B2 | Pyrrolopyridine derivatives and their use as CRTH2 antagonists | NOVARTIS AG (CH) | 2015-10-27 | — | — | US | disclosed |
| US-7022689-B2 | 5-amidino-n-(2-aminophenethyl)-n-hydroxy-benzenesulffonamide derivative, medical composition containing the same, pharmaceutical use thereof and intermediate therefor | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2006-04-04 | — | — | US | disclosed |
| WO-2005123731-A2 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | NOVARTIS AG (CH) | 2005-12-29 | — | — | WO | disclosed |
| US-20050143457-A1 | Novel crystals of 5-hydroxycarbamimidoyl-2-hydroxybenzenesulfonamide derivative | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2005-06-30 | — | — | US | disclosed |
| US-20050107354-A1 | active ingredient a 5-amidino-2-hydroxybenzenesulfonamide derivative or a pharmaceutical acceptable salt thereof; excellent inhibitory effect on mesangial cell proliferation and decreasing effect on urine protein excretion | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2005-05-19 | — | — | US | disclosed |
| US-20050014787-A1 | 5-amidino-2-hydroxybenzenesulfonamide derivatives medicinal compoistions containing the same medicinal use thereof and intermediates in the production thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| EP-1486485-A1 | NOVEL CRYSTALS OF 5-HYDROXYCARBAMIMIDOYL-2-HYDROXYBENZENESULFONAMIDE DERIVATIVE | Kissei Pharmaceutical Co., Ltd. (JP) | 2004-12-15 | — | — | EP | disclosed |
| US-20040242455-A1 | 5-amidino-n-(2-aminophenethyl)-n-hydroxy-benzenesulffonamide derivative, medical composition containing the same, pharmaceutical use thereof and intermediate therefor | KISSEI PAHRMACEUTICAL CO., LTD. (JP) | 2004-12-02 | — | — | US | disclosed |
| EP-1443041-A1 | 5-AMIDINO-2-HYDROXYBENZENESULFONAMIDE DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE SAME, MEDICINAL USE THEREOF AND INTERMEDIATES IN THE PRODUCTION THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2004-08-04 | — | — | EP | disclosed |
| EP-1415983-A1 | 5-AMIDINO-N-(2-AMINOPHENETHYL)-HYDROXYBENZENESULFONAMIDE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND INTERMEDIATE THEREFOR | Kissei Pharmaceutical Co., Ltd. (JP) | 2004-05-06 | — | — | EP | disclosed |
| EP-1331221-A1 | 5-AMIDINO-2-HYDROXYBENZENESULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATES FOR THEIR PREPARATION | Kissei Pharmaceutical Co., Ltd. (JP) | 2003-07-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143457-A1 | Novel crystals of 5-hydroxycarbamimidoyl-2-hydroxybenzenesulfonamide derivative | HABP2, F13B, F5 | TRPV4 2867/4885ALPL 1931/4885AR 4070/4885 |
| US-20050107354-A1 | active ingredient a 5-amidino-2-hydroxybenzenesulfonamide derivative or a pharmaceutical acceptable salt thereof; excellent inhibitory effect on mesangial cell proliferation and decreasing effect on urine protein excretion | REN, GLS, GRB2 | TRPV4 4139/4885ALPL 1478/4885AR 1337/4885 |
| US-20230064417-A1 | COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HRH4, CBR3 | TRPV4 2537/4885ALPL 4745/4885AR 1581/4885 |
| US-20050014787-A1 | 5-amidino-2-hydroxybenzenesulfonamide derivatives medicinal compoistions containing the same medicinal use thereof and intermediates in the production thereof | F2, HYPK, F10 | TRPV4 4682/4885ALPL 1186/4885AR 2503/4885 |
| US-12485169-B2 | Compounds | SLC10A1, VHL, CFTR | TRPV4 3619/4885ALPL 2930/4885AR 319/4885 |
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | EIF2AK4, GCN1, MAPKAPK2 | TRPV4 4119/4885ALPL 4273/4885AR 2943/4885 |
| US-20040242455-A1 | 5-amidino-n-(2-aminophenethyl)-n-hydroxy-benzenesulffonamide derivative, medical composition containing the same, pharmaceutical use thereof and intermediate therefor | F11, F2, F7 | TRPV4 4511/4885ALPL 1449/4885AR 3075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.